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Functional characterisation of the osteoarthritis
susceptibility locus at chromosome 6q14.1 marked
by the polymorphism rs9350591
Katherine Johnson*, Louise N. Reynard and John Loughlin
Abstract
Background: The arcOGEN genome-wide association study reported the rs9350591 C/T single nucleotide
polymorphism (SNP) as marking a region on chromosome 6q14.1 that is associated with hip osteoarthritis (OA) in
Europeans, with an odds ratio (OR) of 1.18 and a p-value of 2.42 × 10−9. rs9350591 is an intergenic SNP surrounded
by seven genes within 1 Mb. Six of the genes are expressed in cartilage. We sought to characterise this signal to assess
whether the association of rs9350591 with OA is mediated by modulating gene expression.
Methods: Total RNA was extracted from hip or knee cartilage of 161 OA patients and from hip cartilage of 29
non-OA patients who had undergone hip replacements as a result of neck-of-femur (NOF) fractures. We used
quantitative PCR (qPCR) to measure overall gene expression, and pyrosequencing to assess allelic expression
of the genes. A mesenchymal stem cell (MSC) differentiation model was used to assess gene expression
during chondrogenesis.
Results: We identified a significant decrease in the expression of SENP6 (p = 0.005) and MYO6 (p = 0.026) in OA hip
cartilage relative to the non-OA hip control cartilage. However, we found no evidence for a correlation between gene
expression and rs9350591 genotype for any of the six genes. In addition, we identified expression quantitative trait loci
(eQTLs) operating on COL12A1, TMEM30A, SENP6 and MYO6, although these were not relevant to the OA associated
signal. Finally, all genes were dynamically expressed during chondrogenesis.
Conclusions: The regulation of gene expression at this locus is complex, highlighted by the down-regulation of SENP6
and MYO6 in OA hip cartilage and by eQTLs operating on four of the genes at the locus. However, modulation of gene
expression in the end-stage OA cartilage that we have investigated is not the mechanism by which this association
signal is operating. As implied by the dynamic patterns of gene expression throughout chondrogenesis, the association
signal marked by rs9350591 could instead be exerting its effects during joint development.
Background
Osteoarthritis (OA) is the most common form of
arthritis, characterised by the age-related progressive
loss of articular cartilage at synovial joints [1]. OA is poly-
genic, with a large number of small-effect risk-conferring
alleles contributing to disease susceptibility [2]. Genome-
wide association scans (GWAS) are powerful tools in the
identification of susceptibility loci due to their use of large
cohorts, independent replication and extensive coverage
without bias towards specific regions [3].
In 2012, the arcOGEN GWAS reported five genome-
wide significant OA association signals in Europeans
[4]. These resulted from the genotyping of almost 1.4
million single nucleotide polymorphisms (SNPs) in a
discovery sample of 7,410 cases and 11,009 controls,
with replication in 14,883 cases and 53,947 controls.
One of the five signals was to the intergenic SNP
rs9350591 on chromosome 6q14.1, with an odds ratio
(OR) of 1.18 for the minor T allele and a p-value of
2.42 × 10−9 in the hip stratum. The association signal
encompasses six genes that are expressed in cartilage
[4]: COL12A1 coding for the α1 polypeptide chain of
type XII collagen, COX7A2 coding for cytochrome c
oxidase 7A2, TMEM30A coding for transmembrane
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protein 30A, FILIP1 coding for filamin A interacting
protein 1, SENP6 coding for sentrin-specific peptidase
6, and MYO6 coding for myosin VI.
It is now clear that the majority of common alleles that
influence polygenic traits do so by regulating gene expres-
sion, so called expression quantitative trait loci, or eQTLs
[5, 6]. Most of these act on nearby genes and are termed
cis-eQTLs. An established example of an OA eQTL is the
GDF5 5′ untranslated region (UTR) SNP rs143383, the
risk-conferring T allele of which correlates with a decrease
in GDF5 expression [7]. More recently, GNL3 and SPCS1,
which reside within an OA association signal on chromo-
some 3p21.1, were shown to be subject to cis-acting poly-
morphisms that influence gene expression in OA joint
tissue [8]. Additionally, DIO2 was subject to the cis-eQTL
actions of rs225014, the risk allele transcript of which was
more abundant in OA cartilage [9].
There are no non-synonymous SNPs residing within
the rs9350591 association region that could account for
the OA signal as the highest r2 is only 0.085 between
rs9350591 and rs17414086 (a C/T SNP in SENP6 coding
for a threonine to methionine substitution). We therefore
hypothesised that, like rs143383 and GDF5, rs9350591
marks a cis-eQTL that accounts for the OA signal at the
6q14.1 locus. To assess this, we investigated the expression
of the genes from within the locus in hip and knee cartil-
age. We first measured overall expression of COL12A1,
COX7A2, TMEM30A, FILIP1, SENP6 and MYO6 using
quantitative PCR (qPCR) and stratified the data by disease
state and by rs9350591 genotype. We subsequently mea-
sured the allelic output of COL12A1, TMEM30A, SENP6
and MYO6 using pyrosequencing to quantify mRNA
synthesised from each allelic transcript. We also used an
in vitro mesenchymal stem cell (MSC) differentiation
model to track the expression of the six genes throughout
chondrogenesis.
Methods
Online database searches
The Broad Institute [10] online software was used to
conduct a search of SNPs in high linkage disequilibrium
(LD; r2 ≥ 0.8) with the association SNP, rs9350591. The
RegulomeDB [11] online database was used to explore
the functionality of the polymorphisms.
Patients
Ethical approval was granted by the Newcastle and North
Tyneside research ethics committee (REC reference num-
ber 09/H0906/72) to collect tissue from two groups of do-
nors: those with primary OA who had undergone elective
total joint replacement of the hip (total hip replacement;
THR) or knee (total knee replacement; TKR), and those
that had undergone a THR a result of a neck-of-femur
(NOF) fracture. The cartilage of the OA patients had
visible lesions and these patients were screened to exclude
OA due to trauma or other pathologies. The NOF patients
showed no signs or symptoms of hip OA, with the cartil-
age being macroscopically intact and with no lesions. The
cartilage was collected from the tibial plateau and the
lateral and medial femoral condyles. For the OA patients,
the cartilage was collected at sites distal to the OA lesion.
Informed written consent for tissue use and data publica-
tion was provided by all donors.
Nucleic acid extraction
Cartilage specimens were snap-frozen at −80 °C on the
day of surgery. The cartilage was ground to a powder
under liquid nitrogen and genomic DNA and total RNA
were extracted using an E.Z.N.A.® DNA/RNA Isolation
Kit (Omega Bio-Tek, Georgia, USA), following the manu-
facturer’s guidelines. Nucleic acid was quantified and
cDNA was synthesised as previously described [12].
Quantitative gene expression analysis
Custom-designed, quality-controlled PrimeTime® TaqMan
primers and probes (Integrated DNA Technologies, USA;
Additional file 1) were used in real-time qPCR to measure
the expression of COL12A1, COX7A2,TMEM30A, FILIP1,
SENP6 and MYO6 in OA and NOF donor cartilage.
Patient details can be found in Additional file 2 and n
numbers can be found in Additional file 3. Reactions were
performed in triplicate on an ABI PRISM 7900HT Se-
quence Detection System (Applied Biosystems, UK), and
the data normalised to that of the housekeeping genes
18S, GAPDH and HPRT1 using the 2-ΔCt method. A
Mann–Whitney U test was performed to assess if gene
expression significantly differed between OA and NOF
cohorts, and between rs9350591 genotypes. Given the
rarity of T allele homozygotes, gene expression was com-
pared between CC homozygotes and T carriers only.
SNP selection
Following a search of publicly available databases for
known transcript SNPs, we selected two transcript SNPs
for allelic expression imbalance analysis per gene for
COL12A1, SENP6, and MYO6, and one transcript SNP
for TMEM30A (Additional file 4). We excluded COX7A2
as there were no known transcript SNPs, and FILIP1
because the transcript SNPs had low minor allele fre-
quencies (MAF; < 5 %).
SNP genotyping
rs9350591 was genotyped by restriction fragment length
polymorphism (RFLP) analysis. All transcript SNP geno-
types were determined by pyrosequencing. The primer
sequences and rs9350591 restriction enzyme used are
listed in Additional file 5.
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Allelic expression analysis
We used pyrosequencing to assess allelic expression im-
balance (AEI) as previously described [8]. Patient details
can be found in Additional file 2 and n numbers can be
found in Additional file 3. Each pyrosequencing assay was
validated using known artificial allelic ratios prior to use
in genotyping and AEI analysis. We performed three
technical replicates, normalising the cDNA allelic ratios to
the mean of the corresponding genomic DNA ratios. A
Mann–Whitney U test was performed to assess the asso-
ciation between AEI ratios and genotype at rs9350591.
Mesenchymal stem cells
MSCs from three young human donors were purchased
from Lonza, UK. MSCs from three OA patients were
harvested from femoral neck aspirates following total
hip replacements. Briefly, trabecular bone was extracted
and passed through a 100 μm cell strainer in a solution
of Dulbecco’s PBS (Life Technologies, UK), 100 U/ml
penicillin and 100 μg/ml streptomycin. The cell mixture
was layered over 10 ml Ficoll-Paque (GE Healthcare,
UK) and centrifuged at 800 g for 40 min at room
temperature. The buffy coat, containing mononuclear
cells, was washed in a solution of Dulbecco’s PBS con-
taining 5 mM EDTA, 0.2 % BSA, 100 U/ml penicillin
and 100 μg/ml streptomycin. Cells were pelleted by
centrifugation at 200 g for 10 min at room temperature.
The wash and centrifugation were repeated once again.
The cell pellet was resuspended in Dulbecco’s PBS,
100 U/ml penicillin and 100 μg/ml streptomycin. Cells
were cultured in a 25 cm2 cell culture flask (Sigma-
Aldrich, UK) for 24 h before the media, supplemented
with 8 ng/ml bFGF (Millipore, UK), was replenished.
Additional file 6 provides details regarding the Lonza
donors and OA patients from whom MSCs were derived.
Mesenchymal stem cell differentiation into chondrocytes
Chondrogenesis was induced by culturing the MSCs in a
cocktail of media and additives including 10 ng/ml TGF-
β3 and 100 nM dexamethasone in a well-established
in vitro differentiation model [13]. In this model, by day
14 the MSCs have created a cartilaginous disc with an
extensive extracellular matrix. RNA was extracted at
days 3, 7 and 14 using TRIzol® Reagent (Life Technologies,
UK) following the manufacturer’s guidelines and cDNA
synthesised as described above.
Results
Database searches to investigate the functionality of the
region surrounding rs9350591
Although there are no publicly available bioinformatics
data pertaining specifically to cartilage, we explored online
databases to interrogate the region in related cell lines. We
found evidence of functionality, including transcription
factor binding and regions with regulatory activity, for
SNPs in perfect or high LD with rs9350591 (Additional
file 7). All of the 39 SNPs with an r2 of 0.8 or above
with rs9350591 are intronic or intergenic, supporting
our hypothesis that rs9350591 marks a cis-eQTL that
accounts for the OA signal at the 6q14.1 locus.
Quantitative comparison of gene expression in cartilage
of hip OA and NOF donors
We quantified COL12A1, COX7A2, TMEM30A, FILIP1,
SENP6, and MYO6 and compared the expression levels
between OA cartilage (knee and hip OA patients com-
bined; n ≥ 68) and NOF cartilage (n ≥ 14; Additional
file 8). This revealed that the expressions of COL12A1
(p = 0.011) and COX7A2 (p = 0.03) were significantly
increased and the expression of SENP6 (p = 0.001) signifi-
cantly decreased in OA. As rs9350591 was identified as
being associated with OA in the hip stratum of the arcO-
GEN study, we next compared gene expression between
OA hip and OA knee (data not shown). We observed a re-
duced expression of MYO6 (p = 0.047) in OA hip relative
to OA knee. Finally, we removed the OA knee samples
from the analyses and directly compared OA hip (n ≥ 19)
and NOF (n ≥ 14; Fig. 1). The expressions of both SENP6
(p = 0.005) and MYO6 (p = 0.026) were reduced in OA hip
relative to NOF.
Quantitative comparison of gene expression in cartilage
stratified by rs9350591 genotype
As highlighted above, all of the SNPs that can account
for the association signal—that is, those that are in an
LD of ≥ 0.8 with rs9350591—are intronic or intergenic
and we can therefore discount the action of a non-
synonymous SNP altering protein structure or function.
This implies that rs9350591 marks a functional role for
one of the 39 polymorphisms in the form of a cis-eQTL.
The fact that the SNPs are in perfect or high LD with
the association signal (all have a D’ of 1 with rs9350591;
Additional file 7) negates the need to genotype all of the
polymorphisms.
To assess if the OA association was acting as an
eQTL on one or more of the six genes, we therefore quan-
tified overall levels of gene expression in OA cartilage (knee
and hip OA patients combined) and stratified the data by
rs9350591 genotype. Of the 74 OA donors whom we
assayed, only two were homozygous for the minor T allele
of rs9350951. This is in close agreement with the calculated
HapMap CEU rs9350591 TT genotype frequency of 1.7 %.
For a robust analysis, we therefore grouped all T allele
carriers (n ≥ 23), that is, minor allele homozygotes (TT)
and heterozygotes (CT), and compared these to major
allele homozygotes (CC; n ≥ 45). We observed no signifi-
cant differences in cartilage gene expression that correlated
with rs9350591 genotype (Additional file 9).
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Again, we removed the OA knee data to allow for the
comparison of OA hip donors only (CC n ≥ 12; T carriers
n = 7; Fig. 2). We observed no significant differences that
correlated with rs9350591 genotype. To corroborate these
findings, we replicated the analysis in an independent co-
hort of 25 additional OA hip donors (CC n ≥ 7; T carriers
n ≥ 4; Fig. 3), and again observed no significant correla-
tions of expression with rs9350591 genotype for any gene.
Fig. 1 Columnar scatter plots of the expression of the six genes in osteoarthritis (OA) and non-OA hip cartilage. Non-OA hip cartilage was obtained
from patients who had undergone a total hip replacement due to a neck-of-femur (NOF) fracture. Gene expression for (a) COL12A1, (b) TMEM30A, (c)
MYO6, (d) SENP6, (e) FILIP1 and (f) COX7A2 was normalised to that of the housekeepers 18S, GAPDH and HPRT1. Each dot represents one donor and n is
the number of donors studied in each group. The horizontal lines represent the mean and the error bars represent the standard error of the mean
(SEM). Statistical significance was assessed using the Mann–Whitney U test and is not corrected for multiple testing. * p < 0.05; ** p < 0.01
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Fig. 2 Columnar scatter plots of the expression of the six genes in osteoarthritis (OA) hip cartilage stratified by genotype at the association SNP
rs9350591. Gene expression for (a) COL12A1, (b) TMEM30A, (c) MYO6, (d) SENP6, (e) FILIP1 and (f) COX7A2 was normalised to that of the housekeepers
18S, GAPDH and HPRT1. Each dot represents one donor and n is the number of donors studied in each group. CC is the major allele homozygote
genotype at the association SNP rs9350591, whilst T carriers are those that are either heterozygote (CT) or minor allele homozygote (TT) at the SNP.
The horizontal lines represent the mean and the error bars represent the standard error of the mean (SEM). Statistical significance was assessed using
the Mann–Whitney U test and is not corrected for multiple testing
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Fig. 3 Columnar scatter plots of the expression of the six genes in a replication cohort of osteoarthritis (OA) hip cartilage stratified by genotype
at the association SNP rs9350591. Gene expression for (a) COL12A1, (b) TMEM30A, (c) MYO6, (d) SENP6, (e) FILIP1 and (f) COX7A2 was normalised to
that of the housekeepers 18S, GAPDH and HPRT1. Each dot represents one donor and n is the number of donors studied in each group. CC is the
major allele homozygote genotype at the association SNP rs9350591, whilst T carriers are those that are either heterozygote (CT) or minor allele
homozygote (TT) at the SNP. The horizontal lines represent the mean and the error bars represent the standard error of the mean (SEM). Statistical
significance was assessed using the Mann–Whitney U test and is not corrected for multiple testing. * p < 0.05
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Allelic expression imbalance analysis of COL12A1,
TMEM30A, SENP6 and MYO6 in cartilage
Correlating genotype with overall gene expression is vul-
nerable to the natural fluctuation in gene expression, such
that subtle genotypic effects on gene expression may be
hidden by inter-individual variation in gene expression,
generating false-negative results. Directly testing for allelic
expression differences within an individual can overcome
this. We therefore identified patients who were heterozy-
gous for transcript SNPs, measured allelic expression by
pyrosequencing in cartilage from these individuals and
then stratified this data by genotype at rs9350591. If this
association SNP correlates with gene expression, then AEI
would be observed in compound heterozygotes, i.e.
individuals heterozygous for both the transcript SNP and
rs9350591, and the AEI ratios would be significantly
different to any AEI ratios observed in individuals
homozygous for rs9350591 (Additional file 10). We were
able to design and validate AEI assays for transcript SNPs
within COL12A1 (rs594012 and rs240736), TMEM30A
(rs41269315), SENP6 (rs71561434 and rs17414687) and
MYO6 (rs1045758 and rs699186). We were unable to per-
form AEI analysis for COX7A2, which has no known tran-
script SNPs, or for FILIP1, whose transcript SNPs have
MAFs < 5 %, which precluded the identification of a suffi-
ciently large number of heterozygotes to do a meaningful
analysis upon. As we aimed to investigate the effect of
rs9350591 genotype specifically on allelic output, it was
not necessary to stratify the data by disease state or joint
site; however to ensure a thorough investigation, we have
included this analysis in Additional file 11. None of the
patients used in this AEI analysis were TT homozygotes at
rs9350591 and our analysis of each of the four genes
therefore involved a comparison of patients who were all
heterozygous at a transcript SNP for that gene and either
homozygous CC (n ≥ 7) or heterozygous CT (n ≥ 7) at
rs9350591. We identified a spread of allelic expression
ratios for all four genes (Fig. 4), which therefore supported
the activity of eQTLs operating at this locus. The AEI was
greatest for MYO6, with allelic ratios in excess of 1.5 for
some individuals. However, these eQTL activities were ob-
served in cartilage from individuals homozygous for
rs9350591 as well as heterozygotes, and as such are not
dependent on genotype at the association SNP. There
were no significant differences (p < 0.05) in the AEI ratios
between CC and CT patients for COL12A1,TMEM30A or
SENP6. There was a significant difference (p = 0.019;
Additional file 11) for MYO6 AEI in OA hip cartilage,
which remained significant upon combining the data
with OA knee and NOF (p = 0.012; Fig. 4), although this
was accounted for by a large allelic ratio spread in those
patients homozygous CC for rs9350591. Therefore, the
AEI of MYO6 is not correlating with the eQTL marked
by rs9350591. Combined with the large number of
statistical tests that we have performed, a p of 0.012
would not endure if corrected for multiple testing; this
implies that rs9350591 does not correlate with AEI at
any of the tested genes.
Quantitative comparison of gene expression during
chondrogenesis
Our data thus far suggests that the OA association
marked by rs9350591 does not correlate with eQTLs
operating in the tested genes in the patient cartilage
tissues analysed. Although OA is a disease in which age
is a predominant risk factor [1], it has been suggested
that several OA genetic susceptibility loci may act either
during skeletal development or throughout life [14]. The
OA association marked by rs9350591 could therefore
be exerting its effect on one or more of the nearby
genes at an earlier stage of cartilage development. Thus,
to assess their potential activity during development,
we tracked the expression of the six genes throughout
chondrogenesis in a well-established in vitro chondro-
genesis model. We studied MSCs from three OA and
three non-OA (Lonza) donors (Additional file 6). All
six genes were expressed throughout chondrogenesis
for both types of donor (Fig. 5). Although there were
inter-individual variations in the levels of expression,
there were no consistent differences between OA and
non-OA. The six genes are therefore active during
cartilage formation.
Discussion
The action of cis-eQTLs has been shown to be an
important mechanism by which OA susceptibility is
mediated. In addition to the GDF5, GNL3/SPCS1 and
DIO2 examples given in the Introduction [7–9], one
other example is the correlation between reduced HBP1
expression in cartilage and the presence of the OA
association alleles of rs3815148 and rs4730250 at the
chromosome 7q22 locus [15]. On this basis, we assessed
whether the OA association signal marked by rs9350591
similarly acted as a cis-eQTL by modulating the expres-
sion of one or more of the six cartilage-expressed genes
residing at the locus.
Our initial analysis revealed a significant increase in
COL12A1 and COX7A2 expression and a decrease in
SENP6 expression in combined OA hip and OA knee
cartilage relative to the non-OA NOF (hip) cartilage.
When the analysis was repeated for OA hip cartilage
only, we observed a significant decrease in MYO6 and
SENP6 expression compared to NOF. From the perspec-
tive of cartilage and OA, none of these four genes have
reported roles in skeletal development or joint biology,
and so we are unable to identify a single OA candidate
gene for further functional analyses. For example, MYO6
encodes the myosin VI protein, an actin-based motor
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protein involved in vesicle trafficking [16] and with path-
ologies related to autosomal dominant hearing loss [17].
However, a role for the protein encoded by SENP6 could
be more relevant. Small ubiquitin-like modifier (SUMO)
proteins can covalently attach to other cellular proteins
in order to regulate their function in a reversible process
known as sumoylation. SENP6 has been shown to con-
trol SUMO regulation by deconjugating the proteins
from their targets [18], and the emerging evidence of a
role of sumoylation in arthritis [19] may make it reason-
able to hypothesise that a decrease in SENP6 expression
could lead to altered downstream protein regulation and
thus be implicated in OA aetiology.
Our analysis of overall gene expression stratified by
genotype did not support a correlation between expres-
sion and the association signal for any of the six genes
tested. This was also the case when we directly assessed
allelic expression in the four genes where this was pos-
sible. These four genes did however have eQTLs operat-
ing on their expression, but these were unrelated to the
association signal. We have to conclude therefore that in
the cartilage tissue that we have investigated, from the
Fig. 4 Columnar scatter plots of allelic expression imbalance (AEI) for four genes in osteoarthritis (OA) cartilage stratified by genotype at the
association SNP rs9350591. AEI for (a) COL12A1, (b) TMEM30A, (c) MYO6 and (d) SENP6. Each dot represents one donor and n is the number of
donors studied in each group. CC is the major allele homozygote genotype at rs9350591 whilst CT is the heterozygote genotype at this SNP. Red
dots are hip (OA and NOF) cartilage and blue dots are OA knee cartilage. Patients showing allelic expression balance have a value of one on the
y-axis whilst deviations from this indicate allelic expression imbalance. Statistical significance was assessed using the Mann–Whitney U test and is
not corrected for multiple testing. * p < 0.05
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elderly patients who form our study group, variation in
expression of the genes is not an OA risk factor.
All six genes demonstrated dynamic expression pat-
terns during chondrogenesis using both OA and younger
MSCs. We speculate therefore that they and their
encoded proteins have functional roles during cartilage
formation. Based on this, it is reasonable to hypothesise
that the association signal could be operating as an
Fig. 5 Gene expression throughout chondrogenesis in an in vitro mesenchymal stem cell (MSC) differentiation model. Gene expression for (a)
COL12A1, (b) TMEM30A, (c) MYO6, (d) SENP6, (e) FILIP1 and (f) COX7A2 was normalised to that of the housekeepers 18S, GAPDH and HPRT1. Measures
were taken from discs harvested at days 3, 7 and 14
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eQTL on one or more of these genes during skeleto-
genesis. Directly testing this hypothesis will however be
arduous due to the scarcity of relevant patient tissues.
Alternatively, the association signal may be operating on
one or more of the six genes but in non-cartilaginous
tissues, or on genes outside of the association interval.
Further analyses are therefore merited but with a focus
away from end-stage diseased cartilage.
Conclusion
In summary, our data reveal a down-regulation of SENP6
and MYO6 in OA hip cartilage relative to non-OA
controls. Investigations should be undertaken to further
understand, in particular, how SENP6 functions in OA
aetiology. We have identified COL12A1, TMEM30A,
SENP6 and MYO6 as being subject to eQTLs in car-
tilage, however, these act independently of rs9350591.
In addition, we have demonstrated the diverse pat-
terns of gene expression during cartilage development.
These findings suggest that the OA susceptibility of this
locus is likely established in an earlier stage of joint devel-
opment. Overall, our results justify further interrogation
of this region.
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